Agenus Overview

  • Year Founded
  • 1994

Year Founded

  • Status
  • Public

  • Employees
  • 316

Employees

  • Stock Symbol
  • AGEN

Stock Symbol

  • Investments
  • 10

  • Share Price
  • $2.08
  • (As of Thursday Closing)

Agenus General Information

Description

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Contact Information

Website
www.agenusbio.com
Formerly Known As
Antigenics, Antigenics Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3 Forbes Road
  • Lexington, MA 02421-7305
  • United States
+1 (781)
Primary Industry
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • 3 Forbes Road
  • Lexington, MA 02421-7305
  • United States
+1 (781)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agenus Stock Performance

As of 17-Apr-2025, Agenus’s stock price is $2.08. Its current market cap is $52.6M with 25.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.08 $1.65 $1.38 - $19.69 $52.6M 25.3M 438K -$10.59

Agenus Financials Summary

As of 31-Dec-2024, Agenus has a trailing 12-month revenue of $103M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 118,835 118,835 312,377 601,040
Revenue 103,463 103,463 156,314 98,024
EBITDA (101,302) (101,302) (145,924) (161,847)
Net Income (227,212) (227,212) (245,761) (220,074)
Total Assets 226,271 226,271 313,913 413,556
Total Debt 94,870 94,870 88,469 78,428
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Agenus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Agenus‘s full profile, request access.

Request a free trial

Agenus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune sys
Drug Discovery
Lexington, MA
316 As of 2024

San Carlos, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Agenus Competitors (58)

One of Agenus’s 58 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Iovance Biotherapeutics Corporation San Carlos, CA
Moderna Formerly VC-backed Cambridge, MA
iTeos Therapeutics Formerly VC-backed Watertown, MA
Bellicum Pharmaceuticals Formerly VC-backed Houston, TX
Compugen Formerly VC-backed Holon, Israel
You’re viewing 5 of 58 competitors. Get the full list »

Agenus Patents

  • 531

    Total Documents Applications and Grants

  • Total Patents Families

  • 208

    Granted

  • 99

    Pending

  • Expiring in next 12 mo

Agenus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023373665-A1 Methods of treating colorectal cancer using an anti-ctla4 antibody Pending 31-Oct-2022
AU-2023231622-A1 Anti-ilt2 antibodies and uses thereof Pending 07-Mar-2022
EP-4490196-A2 Anti-ilt2 antibodies and uses thereof Pending 07-Mar-2022
US-20250109201-A1 Anti-ilt2 antibodies and uses thereof Pending 07-Mar-2022
US-20220389095-A1 Anti-tigit antibodies and methods of use thereof Pending 04-May-2021 C07K16/2803
To view Agenus’s complete patent history, request access »

Agenus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Agenus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Agenus‘s full profile, request access.

Request a free trial

Agenus Investments & Acquisitions (10)

Agenus’s most recent deal was a Merger/Acquisition with CTC North. The deal was made on 22-Feb-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CTC North 22-Feb-2022 Merger/Acquisition Consulting Services (B2B)
Atlant Clinical 20-Apr-2020 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Xoma (Antibody Pilot Plant Facility) 04-Jan-2016 Merger/Acquisition Buildings and Property
PhosImmune 23-Dec-2015 Merger/Acquisition Drug Discovery
Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) 20-Jul-2015 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 10 investments and acquisitions. Get the full list »

Agenus ESG

Risk Overview

Risk Rating

Updated March, 01, 2025

35.96 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Agenus’s complete esg history, request access »

Agenus Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Atlant Clinical Moscow, Russia 2007

Agenus FAQs

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Where is Agenus headquartered?

    Agenus is headquartered in Lexington, MA.

  • What is the size of Agenus?

    Agenus has 316 total employees.

  • What industry is Agenus in?

    Agenus’s primary industry is Drug Discovery.

  • Is Agenus a private or public company?

    Agenus is a Public company.

  • What is Agenus’s stock symbol?

    The ticker symbol for Agenus is AGEN.

  • What is the current stock price of Agenus?

    As of 17-Apr-2025 the stock price of Agenus is $2.08.

  • What is the current market cap of Agenus?

    The current market capitalization of Agenus is $52.6M.

  • What is Agenus’s current revenue?

    The trailing twelve month revenue for Agenus is $103M.

  • Who are Agenus’s competitors?

    Iovance Biotherapeutics, Moderna, iTeos Therapeutics, Bellicum Pharmaceuticals, and Compugen are some of the 58 competitors of Agenus.

  • What is Agenus’s annual earnings per share (EPS)?

    Agenus’s EPS for 12 months was -$10.59.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »